Results 151 to 160 of about 244,373 (296)
This study constructed the W1/O/W2 emulsion–based targeted therapy delivery system for ulcerative colitis (UC) utilizing LCC as surfactant for the first time. This multifunctional emulsion offered certain therapeutic advantages for UC, including targeted colonic delivery of active compounds, synergistic modulation of gut microbiota through combined ...
Qian Wu +9 more
wiley +1 more source
Next-generation mucosal vaccines for respiratory viruses: Immunological correlates, platform design and clinical translation. [PDF]
Younas S +4 more
europepmc +1 more source
A snap‐top delivery nanosystem based on an azobenzene metal–organic framework achieves targeted release of 6‐mercaptopurine via acid‐stable frameworks and hypoxia/pH dual‐responsive β‐cyclodextrin gates. This multifunctional platform integrates three synergistic mechanisms: precision drug delivery to inflammatory sites, intrinsic antioxidant properties
Xin Li +6 more
wiley +1 more source
Hitting the hidden: arming the immune system for the next zoonotic coronavirus spillover. [PDF]
Fricke C, Perlman S.
europepmc +1 more source
A semi‐interpenetrating engineered living material (sIHSELM), fabricated via thermosensitive hydroxybutyl chitosan and covalent protein self‐assembly, demonstrates exceptional mechanical properties and environmental stability. Shielding bacteria from harsh conditions, sIHSELM exhibits remarkable efficacy in ulcerative colitis treatment and pollutants ...
Zixian Bao +8 more
wiley +1 more source
Engineering Microbial Particles for Next‐Generation Biomedical Platforms
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li +7 more
wiley +1 more source
Impaired mucosal IgA response to SARS-CoV-2 in patients with inborn errors of immunity. [PDF]
Zuo F +10 more
europepmc +1 more source
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source
Harnessing mucosal immunity for protective vaccines. [PDF]
Kwon DI +3 more
europepmc +1 more source

